Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

62.24 -5.90 (-8.66%)
Streaming Delayed Price Updated: 1:14 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Top 3 Stocks to Watch: Options Traders Bet on Big Gains
Three stocks have stood out for call option traders to bet on in the coming months as a view for a recovery rally after an S&P 500 sell-off last week 
Via MarketBeat
Topics Stocks
Exposures US Equities
Should You Buy the 3 Worst Nasdaq 100 Stocks Since the Tech Sector Selloff?
The tech sector began selling off in July as investors abandoned former higher fliers, leaving these three as the worst Nasdaq 100 stocks. 
Via InvestorPlace
DexCom, Inc. (DXCM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years
Via Benzinga
Demystifying DexCom: Insights From 15 Analyst Reviews
Via Benzinga
Should You Buy DexCom Stock After Its Post-Earnings Sell-Off?
DexCom now trades at a drastically lower earnings multiple than it has in the past. 
Via The Motley Fool
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
The "Mad Money" host says Dexcom had "a real bad miss... they still really haven't fully explained why that is." 
Via Benzinga
These Stocks Just Dropped by 40% and 15% -- Should You Buy the Dip?
It might be a great time to buy low. 
Via The Motley Fool
Chips, Glorious Chips!
Someone's gotta make 'em, and someone's gotta buy 'em. 
Via The Motley Fool
Is It Time to Buy July's Worst-Performing Nasdaq Stocks?
These three Nasdaq stocks saw price drops of more than 35% last month. Are they good buys or too risky to touch today? 
Via The Motley Fool
Behind the Scenes of DexCom's Latest Options Trends
Via Benzinga
Despite its growth, NASDAQ:DXCM remains within the realm of affordability.
In the world of growth stocks, NASDAQ:DXCM shines as a value proposition. 
Via Chartmill
Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
Hims & Hers stock is showing the market why its fair value is double-digits above where it trades today, with Wall Street analysts to agree 
Via MarketBeat
Topics Bonds ETFs
Exposures Debt Markets
Down 40% in 1 Day, Is DexCom Stock Still a Buy?
Competition and new growth headwinds could derail the stock even further. 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Is Investigating Nano Nuclear, Iris Energy, Ford, and DexCom and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of DexCom, Inc. (DXCM) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H.... 
Via Benzinga
Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Hims & Hers stock is looking like a worthy dip to watch in the coming months, especially as its decline had nothing to do with company operations 
Via MarketBeat
The Law Offices of Frank R. Cruz Announces Investigation of DexCom, Inc. (DXCM) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of DexCom, Inc. (DXCM) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
As Diabetes Battle Heats Up, Spotlight Turns To Dexcom, Abbott
Dexcom is taking on bigger rival Abbott Laboratories with a continuous glucose monitor for non insulin users. 
Via Investor's Business Daily
DexCom, Inc. (DXCM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Jim Cramer Says This Home Improvement Chain Is A Buy Ahead Of Fed Rate Cut Cycle: 'I Would Pick Some Up Tomorrow'
Jim Cramer recommends buying Blackstone Inc. (BX) due to its strong companies and expects Lowe's (LOW) stock to benefit from Federal Reserve's rate cut. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Top 3 Health Care Stocks That May Explode In Q3
Via Benzinga
NASDAQ: DXCM Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (NASDAQ: DXCM) Investors with Significant Losses to Contact the Firm
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
Market Momentum: Your Weekly Financial Forecast
Originally published at VolumeLeaders What to expect for July 29- August 02, 2024 
Via Benzinga
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
DexCom faces several challenges, but GLP-1 drugs aren't big problems for the company right now. 
Via The Motley Fool
ON Semiconductor Posts Upbeat Earnings, Joins Oil States International, CommScope Holding And Other Big Stocks Moving Higher On Monday
Via Benzinga
Tandem Diabetes Care and Dexcom Announce the t:slim X2 Insulin Pump with Dexcom G7 CGM Compatibility is Authorized for Sale by Health Canada
From Tandem Diabetes Care, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.